Category Archives: Clinical Cardiology

WASHINGTON, DCStructural valve deterioration is more common during midterm follow-up among patients with severe symptomatic aortic stenosis treated with a surgical bioprosthesis compared with those who receive the supra-annular, self-expanding transcatheter heart valve (Medtronic), according to a new analysis. The study, which combined data from multiple trials, showed that the rate of structural valve deterioration at 5 years with surgery was 4.38% versus 2.57% in patients undergoing TAVI (P = 0.0095). Michael Reardon, MD (Houston Methodist, TX), who presented the results today during the late-breaking clinical trial session at the American College of Cardiology (ACC) 2022 Scientific Session, said the results are important because they will help physicians in their conversations with patients Continue reading →

Content Baylor College of Medicine announces the signing of a non-exclusive Memorandum of Understanding (MOU) with The Aga Khan University for the exchange of expertise and collaboration on health sciences teaching, research, writing and distribution, and international development. Under the terms of the MOU, Baylor College of Medicine and The Aga Khan University will work collaboratively in a bidirectional manner, leveraging the strengths of both institutions, with the goal of understanding the determinants of cardiometabolic diseases and identifying culturally relevant interventions that mitigate risks associated with cardiometabolic diseases among South Asians. We hope that this bidirectional initiative will allow the generation of new knowledge in the area of cardiometabolic health for South Asians and knowledge sharing between the two institutions, both of which bring rich traditions of academic excellence, said Dr. Continue reading →

SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals Inc., a muscle health-focused biopharmaceutical company developing therapeutics to treat patients experiencing potentially life changing critical illness, announced today the publication of results from its Phase 2 trial of FDY-5301 for the treatment of reperfusion injury following an ST-elevation myocardial infarction (STEMI) in the January 15, 2022 issue of the International Journal of Cardiology. Data from the study known as Iocyte AMI demonstrated the treatment was well-tolerated and provided encouraging signals of potential efficacy in minimizing cardiac damage Continue reading →

New Heart Monitoring Solution Delivers Personalized Heart Health Insights Directly to Your Smartphone Now Easy to Buy and Use: No Prescription Needed for Advanced Heart and Lifestyle Solution REDWOOD CITY, CA / ACCESSWIRE / December 28, 2021 / Biotricity (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced it has expanded the distribution of its new Bioheart heart monitor system, a direct-to-consumer device that offers the same continuous heart monitoring technology used by physicians, on Amazon.com. Last month the company launched commercial sales of its Bioheart device. To improve availability and expand outreach, Biotricity has now listed it for purchase on Amazon.com at: Bioheart on Amazon for $199 with a special introductory price of $149 for a limited time. Continue reading →

Cardiometabolic disease, defined as cardiovascular disease (CVD) or type 2 diabetes (T2D), is the primary comorbidity in patients with cancer. Continue reading →

Embargoed until 7 a.m. Continue reading →

The importance of diagnosing pets in the pre-clinical phase of heart disease, plus the advantages of the classification system. Although veterinarians are often skilled at diagnosing pets with clinical heart failure, it is critical they are skilled at diagnosing those with pre-clinical heart disease as well, according to Amara Estrada, DVM, DACVIM(Cardiology), professor of cardiology at the University of Florida. This proactive approach positively impacts patients by enhancing their quality of life and ultimately helping to delay the disease's development. Continue reading →

Embargoed until 7 a.m. Continue reading →

Some psychiatric medications that can trigger Torsades de Pointes (TdP), a potentially fatal polymorphic ventricular tachycardia that arises during abnormal ventricular repolarization. Are you aware of the risk factors that increase risk of TdP Continue reading →

Philips Interventional Applications Platform IntraSight Mobile Philips Laser System Nexcimer Philips Scoring Balloon Catheter RX AngioSculpt Evo Philips Image Guided Therapy System Azurion November 2, 2021 Philips debuts three new solutions in the North American market that will help drive procedural innovation and workflow efficiency, adding to the companys ecosystem of interventional imaging systems, and diagnostic and therapeutic devices New clinical data presented at TCT 2021: five-year outcomes of iFR-SWEDEHEART trial and new large-scale analysis of Centers for Medicare & Medicaid Services (CMS) data on use of Intravascular Ultrasound (IVUS) in diagnosing and treating peripheral vascular disease Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced North American availability of new innovations in its portfolio of cardiology solutions designed to seamlessly work together, strengthen clinical confidence, build efficiency throughout the care pathway, and improve cardiac care outcomes and experiences. The new updates, aimed at innovating and advancing procedures including percutaneous coronary intervention (PCI) to treat the narrowing of coronary arteries, are being announced at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting (Orlando, USA, November 4-6). Continue reading →